Research Paper Volume 4, Issue 6 pp 436—447

Figure 6. AS101 treatment after disease induction results in partial beneficial effects in the HFD+STZ T2D rat model. (A) Course of experiment. (B) AS101 reduced glucose levels in HFD+STZ T2D rat model. Glucose levels were measured in peripheral blood at different times (*p<0.05 all groups vs. HFD+PBS group, n=6 in each HFD group, n=3 in ND group). (C) AS101 treatment restores proper glucose tolerance. Rats fasted for 12 hours before i.p injection of 2mg/kg glucose. (*p<0.01 versus HFD+PBS+STZ, n=6 in each group). The histogram represents the incremental area under the glucose curve. (D) AS101 (1 mg/kg) treated rats show higher SIRT1 protein levels in liver extract prepared at the end of the experiment. Western blot analysis was done with anti- SIRT1 antibodies; actin was used as a loading control. Error bars represent the ±SEM.